Orthobiologics Market Size | Share and Trends 2024 to 2034

Orthobiologics Market Size and Forecast 2024 to 2034

The global orthobiologics market size is calculated at USD 6.99 billion in 2024 and is expected to reach around USD 11.95 billion by 2034, expanding at a solid CAGR of 5.52% over the forecast period 2024 to 2034. The increasing prevalence of orthopedic procedures coupled with the growing geriatric population is the major factor fostering the orthobiologics market growth. Orthobiologics, also known as regenerative cellular therapies, encompass products that contain or secrete growth factors to aid tissue healing, alleviate pain, and restore normal function. Various orthobiologics available in the market operate through different mechanisms. Autologous orthobiologics are derived from the patient's own body, where, under suitable conditions, they divide to form precursor cells. These products are utilized in treating conditions like fracture recovery and spinal fusion and are available for various body parts, including the hip, knee, ankle, spine, and wrist. Orthobiologics primarily facilitates faster injury healing.

Orthobiologics Market Key Takeaways

• North America dominated the orthobiologics market with the largest market share of 47% in 2023.
• Europe is expected to grow at the fastest rate in the market over the studied period.
• By product, the viscosupplementation segment has contributed more than 40% of market share in 2023.
• By product, the stem cell therapy segment is expected to grow at the fastest rate in the market over the forecast period.
• By application, the spinal fusion segment accounted for the largest market share of 51% in 2023.
• By application, the reconstructive surgery segment is expected to grow at a significant rate in the market over the forecast period.
• By end-use, the hospital segment has held a major market share of 61% in 2023.
• By end-use, the outpatient facilities segment is expected to grow rapidly in the market during the forecast period.

U.S. Orthobiologics Market Size and Growth 2024 to 2034

The U.S. orthobiologics market size was exhibited at USD 1.46 billion in 2023 and is projected to be worth around USD 2.70 billion by 2034, poised to grow at a CAGR of 5.74% from 2024 to 2034.

North America dominated the orthobiologics market in 2023. The rise in degenerative bone disease cases and the increasing popularity of outpatient orthopedic procedures are major contributors to market growth. North America leads the market, largely due to the presence of numerous major companies. The market's projected growth is also driven by an aging population.

• In 2023, the U.S. orthobiologics market held the largest share within North America. The region's strong focus on technological innovation and research continually produces improved orthobiologic products.
• In September 2023, Ossdsign plots a new future as pure play for the U.S.-focused ortho biologics business. Ossdsign AB will abandon its 3D-printed cranial reconstructive implant business to focus on U.S. sales of its Ossdsign Catalyst, an off-the-shelf nano synthetic bone graft that offers gross margins of 90% or better. The new strategy sharply reduces the capital required before the company projects, achieving a positive cash-flow position.

Europe is expected to grow at the fastest rate in the orthobiologics market over the studied period. European market players' strong emphasis on R&D investments and research initiatives, along with favorable health reimbursement policies for bone grafting procedures and a sharp rise in spinal injuries, are projected to boost the demand for orthobiologics in the coming years.

Within Europe, Germany held the largest share of the orthobiologics market, while the UK was the fastest growing. The UK market is expected to see significant growth during the forecast period. The increasing acceptance of orthobiologics as an effective treatment option is driving this market expansion.

• In June 2024, Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), acquired 100% shares of the global orthobiologics business from its long-term partner, B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine.

Orthobiologics Market Growth Factors

• Rising cases of road accidents will drive down the demand for orthobiologics, which can lead to the orthobiologics market growth.
• The increasing number of spinal and orthopedic procedures is expected to drive market growth further.
• High growth potential in developing nations and growing demand for advanced treatment can fuel the orthobiologics market growth shortly.

Orthobiologics Market Scope

Market Dynamics

Driver

Rising prevalence of orthopedic disorders

Over the past decade, there has been a significant rise in the prevalence of orthopedic disorders. Poor dietary habits and inadequate physical activity can disrupt the body's balance, exacerbating these issues. This susceptibility intensifies with age, particularly affecting individuals aged 60 and above, who are more prone to conditions such as arthritis. Those with osteoarthritis in this demographic often endure joint pain and strain in areas like the lower back, hips, and knees. The population of older adults has expanded due to advancements in healthcare, improved life expectancy, and the availability of more sophisticated treatment options. Hence, the increasing incidence of Orthopedic diseases is expected to drive growth in the orthobiologics market.

• In May 2024, OssDsign AB announced that the company would continue its successful penetration of the U.S. orthobiologics market. To date, 5,000 patients have been treated with the innovative nano synthetic bone graft OssDsign Catalyst. The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021.

Restraint

Surging prices for orthobiologics-based treatments

The orthobiologics market's growth could be hampered by increasing patient preference for minimally invasive procedures in the coming years. Additionally, challenges may arise from the adverse impacts associated with Bmp-based therapies. The market expansion might face further constraints due to anticipated price increases in orthobiologics treatments. Stringent production regulations, Complex manufacturing processes, and high operational costs also pose significant challenges to market growth.

Opportunity

The Increase in healthcare expenditure

The orthobiologics market is experiencing significant growth in emerging countries like South Africa, India, and China. These nations are compelled to enhance their healthcare sectors due to the smoothly expanding elderly population, rising per capita incomes, large patient numbers, and heightened awareness. Furthermore, there has been an increase in investment in healthcare infrastructure and facilities within these economies. Although sleep apnea machines are highly effective, their success is limited to a small percentage of cases due to their reliance on consistent use and medical supervision.

• In March 2022, the orthobiologics partnership between MTF Biologics and Orthofix Medical, Inc. expanded. The arrangement includes an expansion agreement for the development of a demineralized bone matrix (DBM), which Orthofix will market under the Legacy brand name and extend Orthofix's exclusive marketing rights to the Trinity allograft line until 2032.

Product Insights

The viscosupplementation segment led the orthobiologics market in 2023. The growing number of osteoarthritis patients and the frequent introduction of new products are expected to drive market growth. Viscosupplementation with hyaluronic acid injections is a popular treatment for osteoarthritis due to its ease of administration and high tolerance, which supports market expansion. Also, the significant demand for minimally invasive surgical treatments and their high acceptance among patients are also considered key factors contributing to market growth.

The stem cell therapy segment is expected to grow at the fastest rate in the orthobiologics market over the forecast period. The global increase in healthcare spending and the raised focus on personalized medicine have fostered a conducive environment for the growth of the stem cell therapy market. Also, progress in biotechnology and regenerative medicine has paved the way for novel techniques and products within the stem cell therapy sector.

• In January 2023, DiscGenics, Inc., a clinical-stage biopharmaceutical company focused on developing cell-based regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to injectable disc cell therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy for the treatment of symptomatic lumbar degenerative disc disease (DDD).

Application Insights

The spinal fusion segment accounted for the largest share of the orthobiologics market in 2023. The benefits of orthobiological products in spinal fusion, such as rapid cell stimulation for bone formation, reduced hospital stays, and fewer follow-up visits, are key factors driving the segment's growth. The increasing number of spinal fusion surgeries globally further boosts the segment's market share. Moreover, leading companies with extensive orthobiologics portfolios for spinal fusion and the growing number of approvals for new products in this area are anticipated to propel market growth in the coming years.

• In February 2022, Orthodox Medical launched a synthetic bioactive bone graft solution, Opus BA, for cervical and lumbar spine fusion procedures. With the solution's full market launch, the company has expanded its synthetic bone growth offerings. Acting as a scaffold, Opus BA allows the bone to grow across the surface and is reabsorbed and replaced with natural bone while healing.

The reconstructive surgery segment is expected to grow at a significant rate in the orthobiologics market over the forecast period. This can be attributed to the rising demand for reconstructive surgery induced by an aging population and a surge in musculoskeletal disorders, which is contributing to the segment's expansion. Moreover, Orthobiologics presents a promising option for improving bone healing, facilitating soft tissue repair, and restoring joint function, thus driving their increased use in reconstructive procedures.

End-use Insights

The hospital segment held the largest share of the orthobiologics market in 2023. A key factor behind the market share dominance is the increasing utilization of orthobiological products in diverse spinal and reconstructive surgeries performed in hospitals. Furthermore, the segment's growth is anticipated to be supported by hospitals' easy access to a wide range of orthobiologics and their specialized patient care. The segment's share is bolstered by frequent readmissions, high patient turnover, and substantial procedure volumes.

The outpatient facilities segment is expected to grow rapidly in the orthobiologics market during the forecast period. This trend is fueled by the rising preference for ambulatory care and same-day surgeries. These facilities offer a convenient and cost-effective solution for patients undergoing minor orthopedic procedures or receiving treatments for sports injuries.

Orthobiologics Market Companies

• NuVasive Inc.
• Arthrex, Inc.
• Globus Medical, Inc.
• Bone Biologics, Corp.
• K2M Group Holdings, Inc.
• Orthofix Medical Inc.
• Bioventus Inc.
• Medtronic PLC
• DePuy Synthes, Inc.
• Bone Solutions Inc.
• Other Key Players

Recent Developments

• In September 2023, Bone Biologics, Corp. Announced positive interim results from the Phase 2 clinical trial of its stem cell therapy for osteoarthritis.
• In October 2023, NuVasive Inc. Launched Simplify Disc Technology, a next-generation interbody fusion device with simplified instrumentation.
• In November 2023, Arthrex, Inc. Launched the Eclipse Meniscal Repair System, a suture-based technique for meniscal repairs.

Segments Covered in the Report

By Product

• Demineralized Bone Matrix (DBM)
• Allograft
• Bone Morphogenetic Protein (BMP)
• Viscosupplementation
• Synthetic Bone Substitutes
• Stem Cell Therapy

By Application

• Spinal Fusion
• Trauma Repair
• Reconstructive Surgery

By End-use

• Hospitals
• Outpatient Facilities

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa